NRX Pharmaceuticals Inc
NRXP
Company Profile
Business description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Contact
1201 Orange Street
Suite 600
WilmingtonDE19801
USAT: +1 484 254-6134
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.50 | 69.70 | -0.75% |
| CAC 40 | 8,340.94 | 20.42 | -0.24% |
| DAX 40 | 26,702.82 | 69.06 | -0.26% |
| Dow JONES (US) | 52,297.09 | 189.40 | -0.36% |
| FTSE 100 | 10,841.79 | 21.30 | -0.20% |
| HKSE | 23,625.14 | 383.41 | -1.60% |
| NASDAQ | 25,366.09 | 100.10 | -0.39% |
| Nikkei 225 | 61,142.35 | 322.99 | 0.53% |
| NZX 50 Index | 14,173.68 | 85.55 | -0.60% |
| S&P 500 | 7,592.40 | 26.98 | -0.35% |
| S&P/ASX 200 | 9,082.20 | 64.60 | -0.71% |
| SSE Composite Index | 3,634.35 | 21.48 | -0.59% |